OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study

Termini, Rosalinda; Žihala, David; Botta, Cirino; Maia, Catarina; Garcés, Juan-José; Terpos, Evangelos; Montaña, Albert Pérez; Jelı́nek, Tomáš; Bargay, Joan; Ocio, Enrique M.; Puerta, José Enrique de la; Martínez‐López, Joaquín; Solano, Fernando; Cabezudo, Maria-Elena; Iglesias, Rebeca; Garcia-Guiñon, Antonio; Casanova, María; Cabañas, Valentín; Hájek, Roman; Ludwig, Heinz; Goldschmidt, Hartmut; Avet‐Loiseau, Hervé; Roccaro, Aldo; San-Miguel, Jesús F.

doi:10.1016/s2152-2650(21)02109-1

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTCs display a promising prognostication potential, which encourages the scientific community to revise current stratifying systems. Their enumeration, moreover, may be particularly useful in the design of new clinical trials as an alternative endpoint (e.g., absence vs. presence of CTCs, specific cutoffs, PB-based MRD) or as a new biomarker for early detection and early intervention of premalignant stages [59,75].…”

Section: Discussionmentioning

confidence: 99%

Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma

Garcés

San-Miguel

2022

Cancers

Self Cite

View full text Add to dashboard Cite

Bone marrow (BM) aspirates are the gold standard for patient prognostication and genetic characterization in multiple myeloma (MM). However, they represent an important limitation for periodic disease monitoring because they entail an aggressive procedure. Moreover, recent findings show that a single BM aspirate is unable to reflect the complex MM heterogeneity. Recent advances in flow cytometry, microfluidics, and “omics” technologies have opened Pandora’s box of MM: The detection and isolation of circulating tumor cells (CTCs) offer a promising and minimally invasive alternative for tumor assessment and metastasis study. CTCs are detectable in premalignant and active MM states, and their enumeration has strong prognostic value, to the extent that it is challenging current stratification systems. In addition, CTCs reflect with high precision both intra- and extra-medullary disease at the phenotypic, genomic, and transcriptomic levels. Despite this high resemblance between tumor clones in distinct locations, some subtle (not random) differences might shed some light on the metastatic process. Thus, it has been suggested that a hypoxic and pro-inflammatory microenvironment could induce an arrest in proliferation forcing tumor cells to recirculate. Herein, we summarize data on the characterization of MM CTCs as well as their clinical and research potential.

show abstract

Section: Discussionmentioning

confidence: 99%

Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma

Garcés

San-Miguel

2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, progression to MM has been associated with decreased CD8 + and memory helper T cells and increased in γδ T and natural killer cells 22 . In addition, evasion of the immune system by changes in myeloma plasma cells also may play a role, but clinical application of these immune deregulation as markers of progression is not widely available, and there are no accessible biomarkers at the moment 23,24 …”

Section: Whom To Treatmentioning

confidence: 99%

Smoldering Myeloma Treatment

Saldarriaga

Rossi²

2021

Cancer J

View full text Add to dashboard Cite

Smoldering multiple myeloma (MM) is a clonal plasma cell disorder characterized by excess marrow involvement and immunoglobulin production. It is the precursor of MM, differing by the lack of end-organ damage. Smoldering MM encompasses a heterogeneous group of patients, with a median risk of progression to active disease of 50% in the first 5 years. Until recently, the standard of care would dictate observation off therapy until the development of end-organ damage. The recognition of high-risk and ultrahigh-risk subgroups of smoldering MM, with more likely evolution to MM, has led to earlier initiation of therapy in the disease course. Ongoing studies to define the ideal timing and patient population are underway, as well as identification of which agents would be of greatest benefit, as the armamentarium for MM continues to grow.

show abstract

OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study

Cited by 2 publications

References 0 publications

Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma

Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma

Smoldering Myeloma Treatment

Contact Info

Product

Resources

About